Kaul U, Chandra S, Bahl V K, Sharma S, Wasir H S
Cardiothoracic Center, All India Institute of Medical Sciences, New Delhi.
Indian Heart J. 1993 Nov-Dec;45(6):469-73.
We have evaluated the effect of enalapril in the prevention of restenosis after percutaneous transluminal coronary angioplasty by a randomized trial conducted on 95 patients. The treatment group (n = 46) received enalapril 10 mg/day besides aspirin with calcium blockers, beginning 24 hours before coronary angioplasty. The conventional medical treatment group (n = 49) received only aspirin and calcium blockers. Enrollment required the presence of angina pectoris and successful dilatation of all significant coronary narrowings. All patients were followed up for at least 6 months. Restenosis was identified by symptoms and exercise testing and confirmed by angiography. The incidence of angiographic restenosis was 34% in the enalapril group and 31% in the conventional treatment group. Long term angiotensin converting enzyme inhibition with enalapril in a dose of 10 mg per day does not prevent restenosis after coronary angioplasty.
我们通过对95例患者进行的一项随机试验，评估了依那普利在经皮腔内冠状动脉成形术后预防再狭窄方面的效果。治疗组（n = 46）除服用阿司匹林和钙阻滞剂外，在冠状动脉成形术前24小时开始每日服用依那普利10毫克。传统药物治疗组（n = 49）仅服用阿司匹林和钙阻滞剂。入选标准为存在心绞痛且所有明显的冠状动脉狭窄均成功扩张。所有患者均随访至少6个月。通过症状和运动试验确定再狭窄，并通过血管造影加以证实。依那普利组血管造影再狭窄的发生率为34%，传统治疗组为31%。每日剂量为10毫克的依那普利长期抑制血管紧张素转换酶并不能预防冠状动脉成形术后的再狭窄。
